Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 18 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 31 Dec 2017.
- 17 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 1 Nov 2017.
- 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.